By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Biotechnology. According to news reporting from Taoyuan, Taiwan, by NewsRx journalists, research stated, "Liposomes can selectively target cancer sites and carry payloads, thereby improving diagnostic and therapeutic effectiveness as well as reducing toxicity. To evaluate therapeutic strategies, it is essential to use animal models reflecting important safety aspects before clinical application."
The news correspondents obtained a quote from the research from the Institute of Nuclear Energy Research, "As our previous study found that a high dosage (185 of MBq) of (188) Re-N,N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine-labeled pegylated liposomes ((188) Re-liposome) induced a decrease in white blood cell (WBC) count in Sprague-Dawley rats 7 days postinjection, the objective of the present study was to investigate extended acute radiotoxicity of (188) Re-liposome. Rats were administered via intravenous (i.v.) injection with (188) Re-liposome (185, 55.5 and 18.5 MBq), normal saline as a blank control or non-radioactive liposome as a vehicle control. Mortality, clinical signs, food consumption, body weights, urinary, biochemical and hematological analyzes were examined. In addition, gross necropsy and histopathological examinations were also performed at the end of the follow-up period. None of the rats died and no clinical sign was observed during the 28-day study period. Only male rats receiving (188) Re-liposome at a high dosage (185 MBq) displayed a slight weight loss compared with the control rats. In both male and female rats, the WBC counts of both high-dose and medium-dose (55.5 MBq) groups reduced significantly 7 days postinjection, but recovered to the normal range on Study Day 29. There was no significant difference in urinary analyzes, biochemical parameters and histopathological assessments between the (188) Re-liposome-treated and control groups."
According to the news reporters, the research concluded: "The information generated from the present study on extended acute toxicity of (188) Re-liposome will serve as a safety reference for radiopharmaceuticals in early-phase clinical trials."
For more information on this research see: Extended acute toxicity study of (188) Re-liposome in rats. Journal of Applied Toxicology, 2013;33(9):886-93. (Wiley-Blackwell - www.wiley.com/; Journal of Applied Toxicology - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1099-1263)
Our news journalists report that additional information may be obtained by contacting L. Chi-Mou, Institute of Nuclear Energy Research, Taoyuan, Taiwan. Additional authors for this research include T. Chia-Che, Y. Chia-Yu, L. Wan-Chi, H. Chung-Li, C. Tsui-Jung, C. Chih-Hsien and L. Te-Wei (see also technology.html">Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Taiwan, Taoyuan, Therapy, Chemistry, Liposomes, Biochemical, Drug Delivery Systems, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC